Advertisement

Acta Neurochirurgica

, Volume 156, Issue 6, pp 1053–1061 | Cite as

Anaplastic astrocytomas: survival and prognostic factors in a surgical series

  • Siril G. RogneEmail author
  • Ane Konglund
  • David Scheie
  • Eirik Helseth
  • Torstein R. Meling
Clinical Article - Brain Tumors

Abstract

Background

To study patient characteristics, prognostic factors and overall survival (OS) in a consecutive, surgical series of WHO grade III anaplastic astrocytomas (AA).

Methods

Patients were identified from a prospective tumor database at Oslo University Hospital, Norway, and patients undergoing surgery for an AA from 2005–2012 were included. Patients’ medical charts were retrospectively reviewed for data collection.

Results

A total of 99 adult patients with histologically verified AA were included. Median age was 52 years (20–81). Biopsy was conducted in 33 % and resection in 67 %. Adjuvant treatment with radiation therapy + temozolomide or radiation therapy only was given in 63 % and 26 %, respectively. The thirty-day mortality rate was 3 %. Median OS was 19 months (95 % CI 11–27 months). Age ≥ 65 years, KPS < 70, biopsy as opposed to resection, and no adjuvant treatment were confirmed negative prognostic factors in multivariate analysis. For patients undergoing resection, presence of postoperative contrast-enhanced tumor, not volume of residual tumor, had significant impact on OS in adjusted analysis.

Conclusions

Median OS following surgery was 19 months, though much variable outcome was observed among subgroups of AA (95 % CI 11–27 months). Age ≥65 years, KPS < 70, biopsy as opposed to resection, and no adjuvant treatment were confirmed negative prognostic factors for OS.

Keywords

Anaplastic astrocytoma High grade glioma Prognostic factors Overall survival Surgery 

Abbreviations

AA

(Anaplastic Astrocytoma)

GBM

(Glioblastoma)

WHO

(World Health Organization)

OS

(Overall Survival)

CI

(Confidence Interval)

RT

(Radiation Therapy)

TMZ

(Temozolomide)

KPS

(Karnofsky Performance Score)

GTR

(Gross Total Resection)

STR

(Subtotal Resection)

ASA

(American Society of Anesthesiologists)

Notes

Acknowledgments

The authors thank Elisabeth Elgsem and Hanne Vebenstad for secretarial assistance.

Conflict of interest and sources of funding

The authors have received no institutional, private or corporate financial support for this study. The authors have no potential conflict of interest.

References

  1. 1.
    Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108:642–648PubMedCrossRefGoogle Scholar
  2. 2.
    Brandes AA, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, Reni M, Rotilio A, Sotti G, Ermani M (2006) Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 8:253–260PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Chaichana KL, Kosztowski T, Niranjan A, Olivi A, Weingart JD, Laterra J, Brem H, Quinones-Hinojosa A (2010) Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosurg 113:286–292PubMedCrossRefGoogle Scholar
  4. 4.
    Combs SE, Nagy M, Edler L, Rausch R, Bischof M, Welzel T, Debus J, Schulz-Ertner D (2008) Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiother Oncol 88:177–182PubMedCrossRefGoogle Scholar
  5. 5.
    Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRefGoogle Scholar
  6. 6.
    Dammers R, Haitsma IK, Schouten JW, Kros JM, Avezaat CJ, Vincent AJ (2008) Safety and efficacy of frameless and frame-based intracranial biopsy techniques. Acta Neurochir (Wien) 150:23–29CrossRefGoogle Scholar
  7. 7.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:1–49CrossRefGoogle Scholar
  8. 8.
    Dripps R (1963) New classification of physical status. Anesthesiol 24:111Google Scholar
  9. 9.
    Grimm SA, Pfiffner TJ (2013) Anaplastic Astrocytoma. Curr Treat Options Neurol 15:302–315PubMedCrossRefGoogle Scholar
  10. 10.
    Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718PubMedCrossRefGoogle Scholar
  11. 11.
    Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3:193–200PubMedCentralPubMedGoogle Scholar
  12. 12.
    Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9:717–726PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of Chemotherapeutic Agents. Columbia University Press, New York, p 196Google Scholar
  14. 14.
    Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS (2006) Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 105:34–40PubMedCrossRefGoogle Scholar
  15. 15.
    Konglund A, Helseth R, Lund-Johansen M, Helseth E, Meling TR (2013) Surgery for high-grade gliomas in the aging. Acta Neurol Scand 128:185–193PubMedCrossRefGoogle Scholar
  16. 16.
    Lassen B, Helseth E, Ronning P, Scheie D, Johannesen TB, Maehlen J, Langmoen IA, Meling TR (2011) Surgical mortality at 30 days and complications leading to recraniotomy in 2630 consecutive craniotomies for intracranial tumors. Neurosurgery 68:1259–1268PubMedGoogle Scholar
  17. 17.
    Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467–473PubMedCrossRefGoogle Scholar
  18. 18.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa AR (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110:156–162PubMedCrossRefGoogle Scholar
  20. 20.
    McGirt MJ, Villavicencio AT, Bulsara KR, Friedman AH (2003) MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. Surg Neurol 59:277–281PubMedCrossRefGoogle Scholar
  21. 21.
    Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S (2007) Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 106:575–581PubMedCrossRefGoogle Scholar
  22. 22.
    Nuno M, Birch K, Mukherjee D, Sarmiento JM, Black KL, Patil CG (2013) Survival and prognostic factors of anaplastic gliomas. Neurosurgery 73:458–465PubMedCrossRefGoogle Scholar
  23. 23.
    Rogne SG, Konglund A, Meling TR, Scheie D, Johannesen TB, Ronning P, Helseth E (2009) Intracranial tumor surgery in patients >70 years of age: is clinical practice worthwhile or futile? Acta Neurol Scand 120:288–294PubMedCrossRefGoogle Scholar
  24. 24.
    Ronning PA, Helseth E, Meling TR, Johannesen TB (2012) A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol 14:1178–1184PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Scoccianti S, Magrini SM, Ricardi U, Detti B, Krengli M, Parisi S, Bertoni F, Sotti G, Cipressi S, Tombolini V, Dall'oglio S, Lioce M, Saieva C, Buglione M, Mantovani C, Rubino G, Muto P, Fusco V, Fariselli L, de Renzis C, Masini L, Santoni R, Pirtoli L, Biti G (2012) Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol 14:798–807PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Shonka NA, Theeler B, Cahill D, Yung A, Smith L, Lei X, Gilbert MR (2013) Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol 113:305–311PubMedCrossRefGoogle Scholar
  27. 27.
    Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMedGoogle Scholar
  28. 28.
    Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576PubMedCrossRefGoogle Scholar
  29. 29.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  30. 30.
    Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF (2012) Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. J Neurooncol 110:227–235PubMedCrossRefGoogle Scholar
  31. 31.
    Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, Caral L, Pujol T, Acebes JJ, Ribalta T, Ferrer I, Graus F (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071PubMedCrossRefGoogle Scholar
  32. 32.
    van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 120:297–304PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329PubMedCrossRefGoogle Scholar
  34. 34.
    Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725–1731PubMedCrossRefGoogle Scholar
  35. 35.
    Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Muller W, Plass C, Weller M, Wick W (2013) Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol 15:1017–1026PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  • Siril G. Rogne
    • 1
    Email author
  • Ane Konglund
    • 1
  • David Scheie
    • 2
  • Eirik Helseth
    • 1
    • 3
  • Torstein R. Meling
    • 1
  1. 1.Department of NeurosurgeryOslo University HospitalOsloNorway
  2. 2.Department of PathologyOslo University HospitalOsloNorway
  3. 3.Faculty of MedicineUniversity of OsloOsloNorway

Personalised recommendations